Publications

  • Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents

    Dimitrios Drekolias et al, Blood Cancer Discovery, 2026 📄

    Featured In: Models, Models, Everywhere: But Which One Should Guide Care 📄

  • RNA shielding of P65 is required to potentiate oncogenic inflammation in TET2 mutated clonal hematopoiesis

    Nana Adjoa Ben-Crentsil et al, Cancer Discovery, 2024 📄

  • Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis

    Nicole Vincelette et al, Blood Cancer Discovery, 2024 📄

    Featured in: MYC expression in myelofibrosis đŸ“ș

    Featured in: Cancer Research Catalyst 📄

  • Transcriptional Plasticity Drives IMiD and p300 Inhibitor Resistance in Multiple Myeloma

    Seongseok Yun et al, Blood Cancer Discovery, 2024 📄

  • Mutations Highly Specific for Secondary AML are Associated with Poor Outcomes in ELN Favorable Risk NPM1-mutated AML

    Onyee Chan et al, Blood Advances, 2024 📄

  • Integrative molecular subtypes of acute myeloid leukemia

    Qianxing Mo et al, Blood Cancer Journal, 2023 📄

  • Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy

    Mario R Fernandez et al, Cancer Research, 2022 📄

  • TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia

    Seongseok Yun et al, Blood Cancer Discovery, 2021 📄

    Featured in: MYC and TFEB control DNA methylation and differentiation in AML 📄

  • Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)

    Seongseok Yun et al, Leukemia, 2021 📄

  • 4EBP1/c-MYC/PUMA and NF-ÎșB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

    Seongseok Yun et al, Blood, 2016 📄

    Featured In: mTOR signaling: new networks for ALL 📄

  • Yun Lab Publications

    Click to View All Yun Lab Publications